Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Rekeland, Ingrid G, Fluge, Øystein, Alme, Kine et al. · Clinical therapeutics · 2019 · DOI
Quick Summary
This study looked at whether the amount of a drug called rituximab in patients' blood predicted whether they would improve from ME/CFS symptoms. The researchers measured rituximab levels in 23 patients and found no clear connection between how much drug was in the blood and who felt better. Interestingly, none of the patients developed antibodies against the drug, which was a potential concern.
Why It Matters
Understanding whether drug levels in the blood correlate with treatment benefit is crucial for evaluating whether rituximab is truly effective for ME/CFS or whether negative results reflect inadequate drug exposure. This study helps clarify the mechanisms of rituximab response and suggests that if this drug works for ME/CFS, it may not depend simply on achieving certain blood concentrations.
Observed Findings
No significant difference in mean serum rituximab concentrations between 14 clinical responders and 9 non-responders.
No patients developed anti-rituximab antibodies (ADAs) at any timepoint during treatment.
Female patients had significantly higher mean serum rituximab concentrations than male patients at 3 months (P = 0.05).
Significant negative correlation between baseline B-cell numbers and rituximab concentration at 3 months (r = -0.47; P = 0.03).
Inferred Conclusions
Clinical improvement in ME/CFS patients was not associated with rituximab serum concentrations or development of ADAs.
The mechanism of any rituximab benefit in ME/CFS, if present, does not appear to depend on achieving particular drug blood levels.
Rituximab pharmacokinetic measurements provide supplementary information but may have limited value for explaining trial outcomes in ME/CFS.
Remaining Questions
Why do some patients show clinical improvement while others do not if drug concentrations are similar, and what alternative mechanisms might explain any therapeutic benefit?
Do sex-based differences in rituximab concentrations have clinical relevance, and are they related to pharmacokinetics or other biological factors?
What This Study Does Not Prove
This study does not prove rituximab is ineffective for ME/CFS—only that drug concentration levels alone do not explain which patients improve and which do not. The observational design prevents causal inference about rituximab efficacy, and the small sample size limits generalizability. The findings also do not rule out other mechanisms of action or potential value in larger, more carefully controlled trials.
How do baseline B-cell characteristics beyond absolute numbers influence rituximab response in ME/CFS?
Should future rituximab trials in ME/CFS employ different dosing strategies, patient selection criteria, or outcome measures to better evaluate efficacy?